Canada’s Intellectual Property Firm

Biosimilars: Comparison chart between Canada, US and Europe

Authored byUrszula Wojtyra

Update: The comparison chart was last updated September, 2020.

As more biosimilars continue to be approved across the world, it is helpful to compare the applicable regimes across major jurisdictions. We have collaborated with Brian Coggio of Fish & Richardson, and Mary Foord-Weston and Camilla Balleny of Carpmaels & Ransford to prepare the chart below comparing relevant considerations for biosimilars in Canada, the US, and Europe, including regulatory pathways, data protection and patent linkage.